A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
Kevin C. Barry(Fred Hutch Cancer Center), Matthew F. Krummel(University of California, San Francisco), Denise M. Wolf, Michael D. Rosenblum(University of California, San Francisco), Adil Daud(University of California, San Francisco), Kimberly Loo(University of California, San Francisco), Michael Alvarado(University of California, San Francisco), Miranda L. Broz(University of California, San Francisco), Bushra Samad(University of California, San Francisco), Joy Hsu(University of California, San Francisco), William R. Ryan(University of California, San Francisco), Nina Bhardwaj(Mount Sinai Hospital), Raj Kumar(Brigham and Women's Hospital), Dusan Bogunovic(Columbia University Irving Medical Center), Francisco J. Cueto(University of California, San Francisco), Patrick K. Ha(University of California, San Francisco), Alexis J. Combes(University of California, San Francisco), Joshua L. Pollack, Amanda E. Nelson(University of North Carolina at Chapel Hill), Mikhail Binnewies(University of California, San Francisco), Vincent Chan(University of California, San Francisco), Saurabh Asthana(University of California, San Francisco)
Cited by 1,009
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k
Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
|Immunity|2016|1.2k
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
|Immunity|2018|937
Dendritic cell-based immunotherapy
|Cell Research|2016|906